Comparison of Clinical Effect Between mFOLFOX6 and FOLFIRI Regimen as Alternately First-and Second-line Therapy on Advanced Gastric Cancer Patients

Objective To observe and compare the efficacy and adverse reactions between mFOLFOX6 and FOLFIRI regimen as alternately first-and second-line chemotherapy on the patients with advanced gastric cancer(AGC).

Methods A total of 62 AGC patients were divided into two groups: Control group, n=32, mFOLFOX6 regimen as the first-line treatment, FOLFIRI regimen as the second-line treatment on 25 patients after disease progression; Observation group, n=30, FOLFIRI regimen as the first-line therapy, mFOLFOX6 regimen as the second-line treatment on 25 patients after disease progression. The efficacy and adverse effects were evaluated.

Results The overall response rates of first-, second-line therapy between control group and observation group were 37.5%, 24.0% and 40.0%, 16.0%, respectively(P=0.801, P=0.662); the median progression-free survival were (5.0±0.25), (2.0±0.36) and (6.0±0.81), (2.0±0.27) months, respectively, with no statistically significant difference (P=0.178, P=0.803); the median overall survival were (10.0±1.06) and (11.0±1.17) months in two groups(P=0.500). The most common toxicities in both groups were myelosuppression, gastrointestinal tract reaction and neurotoxicity. Control group had much higher neurotoxicity than observation group, nevertheless, the rate of diarrhea in observation group was higher than that in control group in first-line treatment.

Conclusion mFOLFOX6 and FOLFIRI regimen have equal effect as alternately first-and second-line treatment on AGC patients, and both can prolong survival with low toxicity.